ConductScience.org, home

Paper39211339

Therapy of IgA nephropathy: time for a paradigm change.

Barratt J and 2 others. Front Med (Lausanne), 2024. Cited by 41 papers, by iCite.

Cite this record

ConductScience Library. Therapy of IgA nephropathy: time for a paradigm change. Papers, record 39211339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39211339

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Therapy of IgA nephropathy: time for a paradigm change.
PubMed
Journal
Front Med (Lausanne)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
41
iCite
Relative citation ratio, by iCite
8.33, provisional
iCite
Revised in PubMed
2024-09-01
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Barratt JJonathan
2Lafayette RARichard A
3Floege JJürgen

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References48

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134247883IgA Nephropathy: Core Curriculum 2021.Am J Kidney Dis2021https://conductscience.org/library/papers/34247883PubMed
229988921Bortezomib for Reduction of Proteinuria in IgA Nephropathy.Kidney Int Rep2018https://conductscience.org/library/papers/29988921PubMed
335967104Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria.Kidney Int Rep2022https://conductscience.org/library/papers/35967104PubMed
415673288Pathways to nephron loss starting from glomerular diseases-insights from animal models.Kidney Int2005https://conductscience.org/library/papers/15673288PubMed
523715783Remnant nephron physiology and the progression of chronic kidney disease.Pediatr Nephrol2014https://conductscience.org/library/papers/23715783PubMed
623782179IgA nephropathy.N Engl J Med2013https://conductscience.org/library/papers/23782179PubMed
734640530Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment.J Clin Med2021https://conductscience.org/library/papers/34640530PubMed
832269271The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis.Sci Rep2020https://conductscience.org/library/papers/32269271PubMed
922318424An update on the pathogenesis and treatment of IgA nephropathy.Kidney Int2012https://conductscience.org/library/papers/22318424PubMed
1037591292Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.Lancet2023https://conductscience.org/library/papers/37591292PubMed
1137914086Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.Kidney Int2024https://conductscience.org/library/papers/37914086PubMed
1236927642EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.Ann Rheum Dis2024https://conductscience.org/library/papers/36927642PubMed
1336685528Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.Front Immunol2022https://conductscience.org/library/papers/36685528PubMed
1434211943Acute Kidney Injury in Pediatric Diabetic Kidney Disease.Front Pediatr2021https://conductscience.org/library/papers/34211943PubMed
1534495361Current treatment of IgA nephropathy.Semin Immunopathol2021https://conductscience.org/library/papers/34495361PubMed
1636351458Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.Lancet2022https://conductscience.org/library/papers/36351458PubMed
1732450154After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.Kidney Int2020https://conductscience.org/library/papers/32450154PubMed
1837705898Clinicopathological Characteristics of Adult IgA Nephropathy in the United States.Kidney Int Rep2023https://conductscience.org/library/papers/37705898PubMed
1912488422Remission of renal disease: recounting the challenge, acquiring the goal.J Clin Invest2002https://conductscience.org/library/papers/12488422PubMed
2033653703Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction.Open Heart2021https://conductscience.org/library/papers/33653703PubMed

See all 48 referencesDownload CSV of references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.

PMIDTitleJournalYearIn PapersSource
42884063From Susceptibility Loci to Therapeutic Targets: The Genetic Architecture of IgA Nephropathy.Int J Mol Sci2026https://conductscience.org/library/papers/42884063PubMed
42787250Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study.Front Immunol2026https://conductscience.org/library/papers/42787250PubMed
42756351Tonsillar Tfh cells contribute to the pathogenesis of IgA nephropathy in collaboration with memory B cells.Front Immunol2026https://conductscience.org/library/papers/42756351PubMed
42746507Twelve-month real-world outcomes of sparsentan in a multicenter Spanish IgA nephropathy cohort.Clin Kidney J2026https://conductscience.org/library/papers/42746507PubMed
42682870Real-world multicenter evidence on Nefecon for attenuating proteinuria and kidney function decline in IgA nephropathy.Front Immunol2026https://conductscience.org/library/papers/42682870PubMed
42668642Toward a Treatment Goal Framework for Emerging Therapies in IgAN: Implications for Future Research.Kidney Int Rep2026https://conductscience.org/library/papers/42668642PubMed
42633049Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.Clin Kidney J2026https://conductscience.org/library/papers/42633049PubMed
42587782Plasma Proteomics in IgA Nephropathy: From Circulating Biomarkers to Molecular Endotypes.Cells2026https://conductscience.org/library/papers/42587782PubMed
42422566Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors.Clin Kidney J2026https://conductscience.org/library/papers/42422566PubMed
42278897Segmental Glomerulosclerosis Subclassification in the Oxford Classification System (MEST-C) Improves the International IgA Nephropathy Prediction Tool.J Clin Med2026https://conductscience.org/library/papers/42278897PubMed
42146603Inhibition of p65 NF-κB enhances production of galactose-deficient IgA1 through suppression of C1GALT1 and SP1 in plasmablast-like cell subpopulations.bioRxiv2026https://conductscience.org/library/papers/42146603PubMed
42121963IgA Nephropathy: Mechanisms, Risk Stratification, and Precision Therapy.Diagnostics (Basel)2026https://conductscience.org/library/papers/42121963PubMed
41904427Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC Nephrol2026https://conductscience.org/library/papers/41904427PubMed
41788457Immunoglobulin A Nephropathy With Associated Thrombotic Microangiopathy: Biopsy and Clinical Case Series.Clin Med Insights Case Rep2026https://conductscience.org/library/papers/41788457PubMed
41573494Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.Cureus2025https://conductscience.org/library/papers/41573494PubMed
41479816Prognostic value of the MEST-C score in long-term outcomes of immunoglobulin A nephropathy patients: Insights from a developing country.World J Nephrol2025https://conductscience.org/library/papers/41479816PubMed
41426049Defining Disease Modification in IgA Nephropathy: Toward a Paradigm Shift in Management.Kidney Int Rep2025https://conductscience.org/library/papers/41426049PubMed
41402784Efficacy and safety of BAFF/APRIL dual antagonists in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC Nephrol2025https://conductscience.org/library/papers/41402784PubMed
41393859Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon.Clin Kidney J2025https://conductscience.org/library/papers/41393859PubMed
41358049Case Report: Maximizing the anti-proteinuric response: a multicenter real-world sparsentan case series in IgA disorders.Front Nephrol2025https://conductscience.org/library/papers/41358049PubMed

See all 32 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AGTR1185PubTator's text mininghttps://conductscience.org/library/genes/185NCBI Gene
TNFSF13B10673PubTator's text mininghttps://conductscience.org/library/genes/10673NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39211339

GET https://conductscience.org/api/papers/v1/39211339/references?page=2